MCRB Seres Therapeutics Inc.

6.9
+0.06  (+1%)
Previous Close 6.84
Open 6.82
Price To Book -5.9
Market Cap 283233684
Shares 41,048,360
Volume 97,912
Short Ratio
Av. Daily Volume 426,912

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1b trial showed no relevant difference in risk of recurrence compared to placebo - company did note was not powered to detect a statistically significant difference in recurrence rates.
SER-262
Primary Clostridium Difficile infection (CDI)
Phase 3 trial initiation announced June 12, 2017. Noted February 7, 2019 that the trial continues to enrol but is evaluating modification of the trial to expedite clinical results.
SER-109 - ECOSPOR III
Recurrent C. Difficile infection
Phase 2b enrolment to be completed mid-2020.
SER-287
Mild-to-Moderate Ulcerative Colitis
Phase 1b data due 2020.
SER-401
Melanoma

Latest News

  1. Seres Therapeutics Presents New Preclinical Data Supporting the Development of SER-401 for Immuno-Oncology at the 2019 American Association for Cancer Research Annual Meeting
  2. Edited Transcript of MCRB earnings conference call or presentation 6-Mar-19 1:30pm GMT
  3. Seres Therapeutics (MCRB) in Focus: Stock Moves 6.7% Higher
  4. Seres Therapeutics Options Volume Peaks After AstraZeneca News
  5. Here's Why Seres Therapeutics Stock Soared Today
  6. Seres teams up with AstraZeneca to explore microbiome benefits in cancer treatment
  7. Seres Therapeutics Announces Microbiome Immuno-Oncology Focused Collaboration with AstraZeneca
  8. Seres Therapeutics Inc (MCRB) Q4 2018 Earnings Conference Call Transcript
  9. Seres Therapeutics Reports Fourth Quarter and Full Year Financial Results and Provides Operational Updates
  10. Seres Therapeutics to Present at Three Upcoming March Conferences
  11. Seres Therapeutics to Host Fourth Quarter and Full Year 2018 Financial Results and Operational Progress Conference Call and Webcast on March 6, 2019
  12. Seres Therapeutics Announces Corporate Changes to Focus on Advancing Clinical Assets
  13. Seres Therapeutics Announces Chief Executive Officer Transition
  14. Does Seres Therapeutics, Inc.’s (NASDAQ:MCRB) CEO Salary Compare Well With Others?
  15. Seres Therapeutics Announces Initiation of SER-287 Phase 2B ECO-RESET Clinical Study for Ulcerative Colitis
  16. Research Report Identifies OraSure Technologies, Sierra Wireless, Seres Therapeutics, Lydall, ChromaDex, and Capricor Therapeutics with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
  17. Edited Transcript of MCRB earnings conference call or presentation 8-Nov-18 1:30pm GMT
  18. Seres Therapeutics to Present at the Stifel 2018 Healthcare Conference
  19. Seres Therapeutics (MCRB) Reports Q3 Loss, Misses Revenue Estimates
  20. Seres Therapeutics Reports Third Quarter Financial Results and Provides Operational Updates